Pelthos Therapeutics Inc. (PTHS)

NYSEAMERICAN: PTHS · Real-Time Price · USD
32.49
+4.69 (16.87%)
Sep 4, 2025, 4:00 PM - Market closed
16.87%
Market Cap98.84M
Revenue (ttm)n/a
Net Income (ttm)-9.04M
Shares Out 3.04M
EPS (ttm)-14.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume25,880
Open29.99
Previous Close27.80
Day's Range27.82 - 32.49
52-Week Range4.50 - 54.29
Betan/a
AnalystsBuy
Price Target50.00 (+53.89%)
Earnings DateAug 13, 2025

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durh... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 11
Stock Exchange NYSEAMERICAN
Ticker Symbol PTHS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for PTHS stock is "Buy" and the 12-month stock price target is $50.0.

Price Target
$50.0
(53.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therap...

17 days ago - GlobeNewsWire